ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
NCT07531745
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Dravet Syndrome
Interventions
DRUG:
ION337
Sponsor
Ionis Pharmaceuticals, Inc.